Hims & Hers Stock (HIMS) Faces a GLP-1 Test as Q1 Earnings Loom
Hims & Hers Health shares rose 10.2% to $28.27 on Friday ahead of first-quarter results due Monday. Analysts expect Q1 revenue near $616.9 million and earnings of 3 cents per share. The company recently reached a deal with Novo Nordisk to offer Ozempic and Wegovy, and added Eli Lilly’s Zepbound and Foundayo to its platform. The FDA is considering tighter rules on compounding GLP-1 drugs.